市場調查報告書
商品編碼
1258862
到 2028 年的飼料抗球蟲藥市場預測——按類型、牲畜、消費模式、形式、來源和地區進行的全球分析Feed Anticoccidials Market Forecasts to 2028 - Global Analysis By Type, Livestock, Mode of Consumption, Form, Source and By Geography |
據Stratistics MRC預測,2022年全球飼料抗球蟲劑市場規模將達到3.7218億美元,預計2028年將達到5.3396億美元,預計將以6.2的CAGR增長% 期間。
飼料抗球蟲劑常用作飼料和獸藥添加劑,用於治療家禽和其他動物的球蟲感染。 這些是由白色鏈黴菌產生的活性物質。 它是一種聚醚離子載體抗生素。 球蟲病是一種同時感染家畜和野生動物的腸道傳染病,球蟲病是畜牧業重大經濟損失的罪魁禍首。
根據畜牧業和乳業部的數據,在印度,雞肉行業貢獻了 75.32%,雞蛋行業貢獻了 24.67%。 此外,2018-2019 年的年雞肉產量為 4.06 公噸。
人們的飲食和消費模式發生了很多變化,越來越多的人吃雞肉。 政府還開展各種活動,以提高公眾對動物健康價值的認識。 動物飼料中使用的抗球蟲劑引起了人們的關注,因為它們對於維持動物免疫力和腸道環境至關重要。 對副作用較少的天然動物飼料添加劑的需求越來越大。 因此,需求正在增加,尤其是家禽生產商。 由於與動物產品消費相關的慢性病患病率上升,用於動物飼料的抗球蟲劑市場正在增長。
由於出現了對用於治療人類和動物感染的抗生素具有耐藥性的微生物,歐盟於 2006 年禁止使用抗生素作為生長促進劑。 自歐盟取消抗生素使用禁令以來,世界上許多國家,尤其是中國、印度和美國,抗生素的使用都出現了下降。 因此,受影響國家的這些抗生素治療收入大幅下降。
飼料抗球蟲病的一個主要驅動因素是家禽中球蟲病發病率的上升。 據說雞等鳥類易患球蟲病,這是一種引起腸道疾病的寄生性原生動物疾病。 近年來,球蟲病變得非常普遍。 對藥物治療具有抗性的新寄生蟲菌株的出現與這一趨勢一致。 此外,新型優質原材料的開發和新興市場的出現,將在預測期內為飼料抗球蟲劑市場創造更多有利可圖和回報豐厚的增長機會。
對各種艾美球蟲藥物的耐藥性和消費者購買不含藥物的家禽產品的壓力是在家禽中使用抗球蟲藥的兩個主要缺點。 在此背景下,研究開始尋找安全的替代品。 大多數這些研究的共同目標是找到含有能有效防止艾美球蟲生長的化合物的植物。 已被評估為具有抗球蟲活性的草藥已成為文獻研究的主題,並且是其提取物。 這些結果可能會限制近期的市場擴張。
最初的 COVID-19 封鎖影響了全球家禽飼料供應並擾亂了物流系統。 最初,世界各地的家禽飼料企業受到監管或關閉,造成畜牧業者飼料短缺。 除了大規模生產停工和供應鏈中斷外,許多製造商還因勞動力短缺而關閉運營,因此食品供應也出現短缺。 由於對 COVID-19 病毒的恐懼以及封鎖使人們無法離開家園,高度依賴自製素食是導致大流行期間飼料抗球蟲藥銷量下降的其他因素。一些。
由於球蟲的存在,家禽中常見的寄生蟲病是使用抗生素。 因此,預計家禽業在預測期內將佔據最大份額。 由於與球蟲同居,感染在腸道中發展。 球蟲中毒會對家禽產生重大的負面影響,並在經濟上擾亂家禽業。 因此,適當的管理對於預防球蟲中毒極為重要。 預防家禽球蟲病的一個主要要求是疫苗接種運動和在預防和治療中使用抗球蟲藥。
在預測期內,鹽黴素部分有望實現良好增長。 Salinomycin 是一種單羧酸聚醚抗生素,由白色鏈黴菌在發酵過程中產生。 鹽黴素的主要作用機制涉及其親離子活性,主要通過與以復雜方式進入牲畜細胞的鉀、鈉、銣和鋰等單價陽離子結合。 與其他抗球蟲藥相比,它們的低成本和現成的可用性使其成為全球增長最快的細分市場。
由於牲畜數量龐大,預計亞太地區在預測期內將佔最大份額。 由於醫療保健成本上升(尤其是在印度和中國)以及過去幾年人們對動物健康意識的增強等因素,亞太地區獸醫保健市場經歷了重大變革。 中國和印度的肉類和家禽生產畜牧業也顯著增加。 畜牧生產者專注於動物保健,並過度使用抗球蟲劑等牲畜抗生素來滿足對牛奶和肉類產品不斷增長的需求。 這些因素正在加速該行業的發展。
預計在預測期內,北美的增長率最高。 該部門的市場需求是由確保家禽產品質量和提高生產率的日益增長的需求驅動的。 此外,政府加大對製藥企業的投資也在擴大市場需求。 在美國之後,加拿大擁有最大的市場份額。 推動該國市場的因素之一是飼養牲畜數量的增加。 據信,對優質肉類產品的需求不斷增長正在加速該地區的市場增長速度。
飼料抗結塊市場的主要參與者是Bioproperties Pty.Ltd.、Ceva Animal Health、Elanco Animal Health、Huvepharma、Impextraco、Kemin Industries、Merck Animal Health、Phibro Animal Health、 Qilu Animal Health Products Co. Ltd.、Virbac S.A、Zydus Animal Health 和 Zoetis。
2023 年 2 月,Elanco Animal Health 宣布增加 PenPoint(TM) Sort,以最大限度地提高養牛者的盈利能力。 PenPoint Sort 增加了現有的 Elanco 知識解決方案服務組合,旨在通過支持數據驅動決策制定的可信工具、技術和洞察力優化運營和產品。
2023 年 2 月,Elanco Animal Health 宣布 Bexacat□(貝格列淨片劑)獲得美國食品和藥物管理局 (FDA) 的批准,這是第一種改善糖尿病貓血糖控制的口服處方藥。 這擴大了 Elanco 的創新貓產品組合,並解決了成年貓對這種慢性疾病未得到滿足的需求。
2022 年 12 月,Ceva Sante Animale 宣布收購專門從事動物保健產品製造和分銷的阿根廷公司 Zoovet,以及開發由 Zoovet 營銷的創新產品的生物技術初創公司 Biotecnofe。
購買此報告的客戶將免費獲得以下定制之一。
According to Stratistics MRC, the Global Feed Anticoccidials Market is accounted for $372.18 million in 2022 and is expected to reach $533.96 million by 2028 growing at a CAGR of 6.2% during the forecast period. Feed anticoccidials are commonly used as an additive in feed and veterinary medications and are used to treat coccidial infections in poultry and other animals. These are substances that are active and made by the bacteria Streptomyces albus. They are polyether ionophore antibiotics. Since coccidiosis is an infectious disease of the intestinal tract that affects both domestic and wild animals, the coccidia are to blame for significant financial losses to the livestock industry.
According to Depart of Animal Husbandry and Dairying, contribution from poultry meat sector was contributed to be 75.32% and poultry egg sector contributed to be 24.67% in India. In addition, the annual production of poultry meat was 4.06 metric tons in the year 2018-2019.
There have been numerous changes in the population's dietary habits and consumption patterns, which have led to a shift towards more people eating poultry. In addition, the government launches a number of campaigns to raise public awareness of the value of animal health. Anticoccidials used in animal feed have drawn a lot of attention because they are essential for maintaining the immunity and gut health of animals. Natural animal feed additives with minimal side effects are becoming more and more in demand. Due to this, demand has increased, primarily among producers of poultry. The market for animal feed anticoccidials is consequently growing due to the rising prevalence of chronic diseases linked to the consumption of animal byproducts.
Due to the emergence of microorganisms that are resistant to antibiotics used to treat human and animal infections, the European Union banned the use of antibiotics as growth promoters in 2006. In many nations around the world, especially in places like China, India, and the United States, the use of antibiotic remedies has decreased since the European Union's ban on their use was lifted. This caused a sizable loss in revenue for these antibiotic treatments in the affected nations.
The primary driver of feed anticoccidial is the rising incidence of coccidiosis in poultry. Chickens and other birds are susceptible to the parasitic protozoa disease coccidiosis, which causes intestinal illness. Coccidiosis has become much more commonplace in recent years. The emergence of new parasite strains that are more resilient to drug treatment coincides with this trend. Additionally, during the forecast period, the development of high-quality and new raw materials as well as emerging new markets will further create lucrative and rewarding growth opportunities for the feed anticoccidials market.
The resistance of various Eimeria spp. to drugs and consumer pressure to buy poultry products free of drug residues were the two main drawbacks to using coccidiostats in poultry. This circumstance served as a catalyst for research into finding secure alternatives. Finding plants with compounds that are effective at preventing Eimeria spp. from multiplying was the common goal of the majority of these studies. The evaluated herbs with anticoccidial properties have been the subject of documented studies and their extracts. These outcomes may limit market expansion in the near future.
The initial COVID-19 lockdown affected the global supply of poultry feed and disrupted the logistics system. In the beginning, there had been restrictions and closures of poultry feed businesses all over the world, which led to a shortage of feed for livestock farmers. The supply of food products was insufficient as many of the manufacturers shut down due to a labor shortage, along with mass production shutdowns and supply chain disruptions. The high reliance on home-prepared vegetarian food as a result of the COVID-19 virus fear and the lockdown that prevented people from leaving their homes are a couple of the other factors that contributed to the decline in sales of feed anticoccidial during the pandemic.
Due to the presence of coccidia, one of the more common parasitic diseases in poultry is the use of antibiotics. Therefore, the poultry segment is expected to register the largest share during the forecast period. As a result of co-limiting the coccidia, this infectious infection develops in the intestine. Coccidial poisoning can have a significant negative impact on poultry, and it has the potential to economically disrupt the poultry industry. For this reason, it is crucial to put in place the proper controls to stop any coccidial poisoning. The main requirements to stop coccidiosis in poultry are vaccination campaigns and the use of anti-coccidiotic medications for both prophylaxis and treatment.
During the forecast period, the salinomycin segment is expected to witness lucrative growth. Salinomycin is an antibiotic that is a monocarboxylic polyether and is produced when Streptomyces albus ferments. Salinomycin's primary mechanism of action involves ionophoric activity, primarily through the binding of monovalent cations like potassium, sodium, rubidium, and lithium, which are then channeled into livestock cells in a complex manner. It is the fastest-growing market segment globally due to its lower cost compared to other anticoccidials and easy availability.
Owing to the enormous number of domesticated animals in the region, Asia Pacific is expected to witness the largest share over the forecast period. Due to factors like rising health spending, particularly in India and China, and growing awareness of animal health over the past few years, the animal healthcare market in Asia Pacific has undergone significant changes. Significant increases in livestock breeding for the production of meat and poultry were also observed in China and India. Livestock producers are putting more emphasis on animal healthcare and overusing livestock antibiotics, such as anticoccidials, to satisfy the rising demand for milk and meat products. Such elements are accelerating the growth in this area.
During the forecast period, North America is anticipated to register the highest growth rate. The market's need in this area is being driven by an increase in the need to guarantee the quality of poultry products and an increase in production rates. Moreover, the government's increasing investments in pharmaceutical firms also broaden the market's demand. Following the United States in capturing the largest market share is Canada. One of the main drivers of market expansion in this nation is the expansion of the livestock population. The increasing demand for high-quality meat products is credited with accelerating the market's growth rate in this region.
Some of the key players profiled in the Feed Anticoccidials Market include: Bioproperties Pty. Ltd., Ceva Animal Health, Elanco Animal Health, Huvepharma, Impextraco, Kemin Industries, Merck Animal Health, Phibro Animal Health, Qilu Animal Health Products Co. Ltd., Virbac S.A, Zydus Animal Health and Zoetis.
In February 2023, Elanco Animal Health announces the addition of PenPoint™ Sort to help cattle feeders maximize profitability. PenPoint Sort adds to the existing Elanco Knowledge Solutions portfolio of services designed to optimize practices and products through trusted tools, technologies and insights to empower data-driven decision making.
In February 2023, Elanco Animal Health announced the U.S. Food and Drug Administration (FDA) approved Bexacat™ (bexagliflozin tablets), the first orally administered prescription medication to improve glycemic control in cats with diabetes mellitus, expanding Elanco's innovative feline portfolio while addressing an unmet need for this chronic condition in adult cats.
In December 2022, Ceva Sante Animale (Ceva) announces the acquisition of the Argentinian companies Zoovet - specialized in the production and marketing of animal health products and Biotecnofe - a biotech start-up developing innovative products to be distributed by Zoovet.
All the customers of this report will be entitled to receive one of the following free customization options: